Article Versions Notes

Paret C, Ustjanzew A, Ersali S, Seidmann L, Jennemann R, Ziegler N, Malki KE, Russo A, Wingerter A, Ortmüller F, et al. GD2 Expression in Medulloblastoma and Neuroblastoma for Personalized Immunotherapy: A Matter of Subtype. Cancers. 2022; 14(24):6051. https://doi.org/10.3390/cancers14246051

Paret, Claudia, Arsenij Ustjanzew, Sara Ersali, Larissa Seidmann, Richard Jennemann, Nicole Ziegler, Khalifa El Malki, Alexandra Russo, Arthur Wingerter, Franziska Ortmüller, and et al. 2022. "GD2 Expression in Medulloblastoma and Neuroblastoma for Personalized Immunotherapy: A Matter of Subtype" Cancers 14, no. 24: 6051. https://doi.org/10.3390/cancers14246051

Paret, C., Ustjanzew, A., Ersali, S., Seidmann, L., Jennemann, R., Ziegler, N., Malki, K. E., Russo, A., Wingerter, A., Ortmüller, F., Bornas, A., Wehling, P. C., Lepădatu, A., Ottenhausen, M., Roth, W., Sommer, C., Fliss, B., Frauenknecht, K. B. M., Sandhoff, R., & Faber, J. (2022). GD2 Expression in Medulloblastoma and Neuroblastoma for Personalized Immunotherapy: A Matter of Subtype. Cancers, 14(24), 6051. https://doi.org/10.3390/cancers14246051